Hutchison China MediTech, also known as HUTCHMED, has disclosed an exclusive development and licensing agreement with a subsidiary of GlaxoSmithKline, granting the GSK subsidiary global rights, excluding Mainland China, Hong Kong, Macau, and Taiwan, to develop and commercialize HMPL-A830. The clinical development will initially focus on indications for colorectal, pancreatic, and lung cancers. The agreement involves an initial payment of $110 million and potential milestone payments for development, registration, and commercialization totaling up to $1.295 billion, plus royalties based on net sales. HMPL-A830 is a first-in-class Antibody-Drug Conjugate (“ATTC”) candidate drug, comprising a highly selective, potent KRAS (Kirsten Rat Sarcoma)…
News Timeline:
Track the development of this news story across the Internet.